Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) CAO Rakhi Kumar sold 250,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the completion of the sale, the chief accounting officer now directly owns 209,322 shares in the company, valued at approximately $2,488,838.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Roivant Sciences Price Performance
ROIV traded down $0.21 during midday trading on Tuesday, hitting $11.69. The company had a trading volume of 20,026,589 shares, compared to its average volume of 6,111,174. Roivant Sciences Ltd. has a twelve month low of $8.24 and a twelve month high of $13.24. The firm’s 50-day simple moving average is $11.47 and its 200-day simple moving average is $11.06. The company has a market capitalization of $8.64 billion, a PE ratio of 2.31 and a beta of 1.25. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.33. The firm had revenue of $55.10 million for the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The business’s revenue for the quarter was up 155.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.38) EPS. Equities research analysts predict that Roivant Sciences Ltd. will post -1.14 EPS for the current fiscal year.
Hedge Funds Weigh In On Roivant Sciences
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Thursday, September 19th. Piper Sandler increased their price objective on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Finally, Bank of America boosted their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.39.
View Our Latest Research Report on Roivant Sciences
Roivant Sciences Company Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
- Five stocks we like better than Roivant Sciences
- What Makes a Stock a Good Dividend Stock?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- NYSE Stocks Give Investors a Variety of Quality Options
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.